Rhumbline Advisers Acquires 15,792 Shares of Edwards Lifesciences Corporation $EW

Rhumbline Advisers raised its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 1.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 1,111,787 shares of the medical research company’s stock after acquiring an additional 15,792 shares during the period. Rhumbline Advisers owned approximately 0.19% of Edwards Lifesciences worth $86,464,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Krilogy Financial LLC bought a new position in shares of Edwards Lifesciences in the 3rd quarter worth $427,000. Advisors Asset Management Inc. lifted its stake in Edwards Lifesciences by 10.7% in the third quarter. Advisors Asset Management Inc. now owns 17,883 shares of the medical research company’s stock valued at $1,391,000 after buying an additional 1,727 shares during the period. Stratos Wealth Partners LTD. boosted its holdings in Edwards Lifesciences by 39.4% during the third quarter. Stratos Wealth Partners LTD. now owns 14,659 shares of the medical research company’s stock worth $1,140,000 after buying an additional 4,142 shares during the last quarter. MQS Management LLC bought a new position in Edwards Lifesciences during the third quarter worth about $307,000. Finally, Wealthfront Advisers LLC grew its position in shares of Edwards Lifesciences by 7.6% during the 3rd quarter. Wealthfront Advisers LLC now owns 29,662 shares of the medical research company’s stock worth $2,307,000 after buying an additional 2,083 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,700 shares of the stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the transaction, the chief financial officer directly owned 39,898 shares in the company, valued at approximately $3,370,184.06. This trade represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,885,571.40. This represents a 4.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 43,804 shares of company stock valued at $3,699,082 over the last three months. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences News Roundup

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Analyst upgrades and reiterated buys lift longer‑term outlook — Wells Fargo raised its price target to $100 and moved to “overweight,” while BTIG and several other firms reiterated Buy ratings with ~$103 targets, supporting upside expectations. Article Title
• Positive Sentiment: Strong revenue growth and TAVR momentum highlighted on the earnings call — Management emphasized sustained Transcatheter Aortic Valve Replacement (TAVR) and other structural‑heart growth drivers; the company is leaning into growth after the quarter. Article Title
• Positive Sentiment: Options/contrarian take: some traders see the post‑earnings weakness as a buying opportunity — commentary suggests cleared uncertainty after results could support a tactical bullish trade. Article Title
• Neutral Sentiment: Mixed earnings print — Q4 revenue topped expectations and grew year‑over‑year, but EPS missed estimates. Revenue strength supports the growth narrative, while the EPS shortfall creates near‑term uncertainty. Article Title
• Neutral Sentiment: Sector context — Comparative coverage of healthcare earnings (AstraZeneca vs. Edwards vs. Zimmer Biomet) highlights macro/peer performance but is not specific to EW’s fundamentals. Article Title
• Negative Sentiment: Shareholder‑rights notice from Halper Sadeh LLC adds legal/uncertainty risk — a public call encouraging shareholders to contact the firm can prompt selling or increase perceived governance risk. Article Title

Wall Street Analysts Forecast Growth

EW has been the topic of a number of analyst reports. Citigroup reiterated a “buy” rating and issued a $101.00 price target (up from $96.00) on shares of Edwards Lifesciences in a research report on Thursday, December 11th. Royal Bank Of Canada upped their target price on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, December 5th. JPMorgan Chase & Co. raised shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $90.00 to $100.00 in a research report on Thursday, December 18th. Piper Sandler restated an “overweight” rating and issued a $100.00 price objective (up previously from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday. Finally, Raymond James Financial raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective on the stock in a research note on Monday, November 3rd. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $96.14.

Edwards Lifesciences Stock Down 3.7%

Shares of EW stock opened at $76.39 on Friday. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The firm has a fifty day moving average of $83.55 and a 200-day moving average of $81.10. The company has a market capitalization of $44.33 billion, a price-to-earnings ratio of 41.74, a P/E/G ratio of 3.03 and a beta of 0.94.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). The company had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company’s revenue was up 13.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.